L. Vijayachandran, S. Xavier, K. Sundaram, L. Biswas, D. Panikar, B. Rajamma, S. Nair, K. Menon
{"title":"Molecular analysis of oncogene expressions in different grades of gliomas","authors":"L. Vijayachandran, S. Xavier, K. Sundaram, L. Biswas, D. Panikar, B. Rajamma, S. Nair, K. Menon","doi":"10.5584/JIOMICS.V8I1.242","DOIUrl":null,"url":null,"abstract":"The aggressiveness of brain tumors is attributed to the expression of multiple oncogenes involved in proliferation, metabolism and therapeutic resistance whose potential correlation with tumor progression has not been well-studied. In this study, we aimed to investigate the relationship of oncotargets involved in pathogenesis with respect to glioma grades. Gliomas ( n =40) were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and sequencing for the detection of epidermal growth factor receptor ( EGFR ) mutants. Expressions levels of EGFR , EGFR variant III ( EGFRvIII ), Lck/Yes novel tyrosine kinase ( LYN ), Spleen tyrosine kinase ( SYK ), insulin receptor substrate 1 ( IRS1 ), phosphatidylinositol 3-kinase ( PI3K ), Src homology 2 domain-containing inositol 5-phosphatase 1 ( SHIP1 ) and glucose transporter 3 ( GLUT3 ) were studied using real-time PCR and compared against glioma grades via statistical methods. Protein expressions were analyzed using immunohistochemistry and western blotting. EGFRvIII was detected in 53% and exon 4 deletion ( de4 EGFR ) in 20% of gliomas. Importantly, the expressions levels of candidate oncogenes were significantly upregulated ( P","PeriodicalId":37675,"journal":{"name":"Journal of Integrated OMICS","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5584/JIOMICS.V8I1.242","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrated OMICS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5584/JIOMICS.V8I1.242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 1
Abstract
The aggressiveness of brain tumors is attributed to the expression of multiple oncogenes involved in proliferation, metabolism and therapeutic resistance whose potential correlation with tumor progression has not been well-studied. In this study, we aimed to investigate the relationship of oncotargets involved in pathogenesis with respect to glioma grades. Gliomas ( n =40) were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and sequencing for the detection of epidermal growth factor receptor ( EGFR ) mutants. Expressions levels of EGFR , EGFR variant III ( EGFRvIII ), Lck/Yes novel tyrosine kinase ( LYN ), Spleen tyrosine kinase ( SYK ), insulin receptor substrate 1 ( IRS1 ), phosphatidylinositol 3-kinase ( PI3K ), Src homology 2 domain-containing inositol 5-phosphatase 1 ( SHIP1 ) and glucose transporter 3 ( GLUT3 ) were studied using real-time PCR and compared against glioma grades via statistical methods. Protein expressions were analyzed using immunohistochemistry and western blotting. EGFRvIII was detected in 53% and exon 4 deletion ( de4 EGFR ) in 20% of gliomas. Importantly, the expressions levels of candidate oncogenes were significantly upregulated ( P
期刊介绍:
JIOMICS provides a forum for the publication of original research papers, letters to the editor, short communications, and critical reviews in all branches of pure and applied –omics subjects, such as proteomics, metabolomics, metallomics and genomics. Especial interest is given to papers where more than one –omics subject is covered. Papers are evaluated based on scientific novelty and demonstrated scientific applicability. Original research papers on fundamental studies, and novel sensor and instrumentation development, are especially encouraged. Novel or improved findings in areas such as clinical, medicinal, biological, environmental and materials –omics are welcome.